This is a type of anemia, which means your blood doesn't have enough healthy red blood cells. In this specific type, the bone marrow is making too many immature blood cells, called blasts. These blasts are abnormal and can crowd out the normal cells. It's called 'refractory' because it doesn't respond well to standard treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Decitabine for Refractory Anemia with Excess of Blasts?
Refractory anemia with excess blasts (RAEB) is a type of myelodysplastic syndrome, or MDS, a group of cancers in which the bone marrow stops making enough healthy blood cells. Normally, immature cells in the marrow develop into red blood cells that carry oxygen, white blood cells that fight infection and platelets that help blood clot. In MDS, many of these cells never mature properly. The result is low blood counts, most often anemia, which can cause tiredness and shortness of breath, sometimes along with infections or easy bruising and bleeding. What sets RAEB apart is the number of blasts, the very immature cells that normally make up only a small share of the marrow. In RAEB, blasts make up 5% to 19% of the cells in the bone marrow. That higher blast count makes it one of the more serious forms of MDS, because it can progress to acute myeloid leukemia (AML), a fast-growing blood cancer. Once blasts reach 20%, the disease is classified as AML. RAEB is an older name that many reports and drug labels still use. Doctors now usually call it MDS with excess blasts or, in the current World Health Organization system, MDS with increased blasts. It is split into two levels: 5% to 9% marrow blasts (RAEB-1, now MDS-IB1) and 10% to 19% (RAEB-2, now MDS-IB2), with the second carrying a higher risk of turning into leukemia.
MDS starts when bone marrow stem cells acquire changes in their DNA, so the marrow produces abnormal cells. In most people, no specific cause is found. It is not contagious, and it usually is not inherited, although a small number of people carry inherited gene changes that make marrow cancers more likely. Age is the strongest risk factor. MDS is rare overall and most often diagnosed in people over 60, with a typical age at diagnosis around 70, and it is somewhat more common in men. Past chemotherapy or radiation therapy for another cancer raises the risk; MDS that follows such treatment is called therapy-related and tends to be harder to treat. Long-term exposure to tobacco smoke, benzene and some other solvents, pesticides and heavy metals has also been linked to higher risk. Having a risk factor does not mean a person caused their disease, and many people with MDS have none.
RAEB is often first suspected from a routine blood test. A complete blood count (CBC) may show low red cells, low white cells or low platelets, and a doctor will look at a blood smear under the microscope for oddly shaped cells or blasts. Blood tests for vitamin B12, folate, iron and other causes help rule out more common reasons for anemia. The diagnosis itself needs a bone marrow aspiration and biopsy, in which a needle removes a small sample of liquid marrow and bone, usually from the back of the hip, after the area is numbed. A pathologist counts the share of blasts in the marrow, since that number separates RAEB from lower-risk MDS (under 5% blasts) and from AML (20% or more). The sample is also tested for chromosome changes and often for gene mutations. These results feed into a risk score, most often the Revised International Prognostic Scoring System (IPSS-R), which combines the blast percentage, the chromosome findings and how low each blood count is. Most people with RAEB fall into a higher-risk group, and this score, along with age and overall health, guides how aggressive treatment should be.
Because RAEB carries a real chance of becoming leukemia, treatment usually aims to control the disease and help people live longer, not only to relieve anemia. The plan depends largely on the risk score, age, overall fitness and the person's own goals. A donor stem cell transplant (allogeneic transplant) is the only treatment that can cure MDS. It uses chemotherapy, sometimes with radiation, to clear the diseased marrow, followed by an infusion of blood-forming cells from a matched donor. In selected people it can lead to long-term cure, but it carries a substantial risk of serious complications and death, which limits who can have it. Lower-intensity preparation has made transplant possible for some older adults, so eligibility is decided individually, often soon after diagnosis. For many people, the main treatment is a hypomethylating agent, a type of drug that helps switch back on genes the cancer has silenced and kills fast-dividing abnormal cells. Azacitidine (Vidaza) is given as injections under the skin or into a vein for several days each month. In a large trial of people with higher-risk MDS, it extended median survival from about 16 to 24 months compared with conventional care. Decitabine is a related drug, available as a tablet combined with cedazuridine (Inqovi). These medicines often need several monthly cycles, sometimes up to six, before counts improve, they usually continue as long as they keep working, and they do not cure the disease. They can lower blood counts further at first, so frequent blood tests are part of treatment. Some people, especially those with higher blast counts who are fit, receive intensive chemotherapy like that used for AML, often as a bridge to transplant. Supportive care runs alongside every option: red cell transfusions for anemia, platelet transfusions for bleeding and antibiotics for infections. People who need many transfusions can build up excess iron and may need medicine to remove it. Clinical trials are an important option, particularly if the disease stops responding.
RAEB is a serious diagnosis, and the course varies widely. Some people stay stable on treatment for a long time, while in others the blast count rises and the disease turns into AML. Low blood counts themselves cause many of the problems people face, and infections and bleeding are a leading cause of serious illness even before any change to leukemia. Older survival estimates for RAEB were measured in months to a few years, but those figures predate current treatment and cannot predict any one person's outcome. A hematologist can give a more personal estimate based on the risk score and response to treatment. Daily life often revolves around fatigue, regular clinic visits and blood tests. Hypomethylating treatment usually means about a week of treatment each month, and transfusions may be needed every few weeks. Because white counts can be low, people are usually advised to take care with infection risks, such as hand-washing and avoiding sick contacts. Transplant, if chosen, involves weeks in or near a transplant center, months of recovery and long-term follow-up. Repeat bone marrow tests are used to check whether treatment is working. It is reasonable to discuss goals of care early, including how much treatment burden fits a person's priorities, and to involve family and caregivers in planning.
See a doctor if you have ongoing tiredness, shortness of breath, pale skin, easy bruising or frequent infections, especially if a blood test has shown low counts. If you have RAEB, tell your care team at your next contact if fatigue or breathlessness is getting worse, since that can mean anemia is deepening and a transfusion or treatment change may be needed. Contact your care team right away, using their after-hours number if needed, if you develop a fever of 100.5°F (38°C) or higher or shaking chills. With low white cells, infections can become life threatening quickly, and fever-reducing medicine can hide them, so call before taking any. Also call right away for bleeding that does not stop after a few minutes, black or bloody stools, pink or red urine, or a bad headache, vision change or confusion, which can signal bleeding when platelets are low.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Refractory Anemia with Excess of Blasts is like, what's helped you, or ask the community a question.